Meeting
2017 ASCO Annual Meeting
Lenalidomide, doxorubicin hydrochloride, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.
Presenter
Stefan Knop, MD
Medizinische Klinik und Poliklinik II, Julius Maximilians Universität Würzburg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01685814
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8001)
DOI
10.1200/JCO.2017.35.15_suppl.8001
Abstract #
8001
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Speaker: Michael Andrew Postow, MD
Videos & Slides
2022 ASCO Annual Meeting
ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.
Speaker: Dominik Dytfeld, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
Speaker: Paul G. Richardson, MD